JP2010539160A - 抗糖尿病作用を備える医薬組成物 - Google Patents

抗糖尿病作用を備える医薬組成物 Download PDF

Info

Publication number
JP2010539160A
JP2010539160A JP2010524811A JP2010524811A JP2010539160A JP 2010539160 A JP2010539160 A JP 2010539160A JP 2010524811 A JP2010524811 A JP 2010524811A JP 2010524811 A JP2010524811 A JP 2010524811A JP 2010539160 A JP2010539160 A JP 2010539160A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
optionally substituted
general formula
methyl
carboethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010524811A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539160A5 (https=
Inventor
デミン，アレクサンドル・ヴィクトロヴィッチ
マルティアノフ，ヴィタリー・アファナシエヴィッチ
シュスター，アレクサンドル・ミハイロヴィッチ
Original Assignee
ザクリトー・アクチオネルノー・オブシェストヴォ “マスタークローン”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザクリトー・アクチオネルノー・オブシェストヴォ “マスタークローン” filed Critical ザクリトー・アクチオネルノー・オブシェストヴォ “マスタークローン”
Publication of JP2010539160A publication Critical patent/JP2010539160A/ja
Publication of JP2010539160A5 publication Critical patent/JP2010539160A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2010524811A 2007-09-14 2008-05-22 抗糖尿病作用を備える医薬組成物 Pending JP2010539160A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2007134267/15A RU2361581C2 (ru) 2007-09-14 2007-09-14 Фармацевтическая композиция, обладающая противодиабетической, гиполипидемической, гипогликемической и гипохолестеринемической активностью, способ ее получения и способы лечения указанных заболеваний
PCT/RU2008/000320 WO2009035368A1 (en) 2007-09-14 2008-05-22 Antidiabetic pharmaceutical composition

Publications (2)

Publication Number Publication Date
JP2010539160A true JP2010539160A (ja) 2010-12-16
JP2010539160A5 JP2010539160A5 (https=) 2011-07-07

Family

ID=40452228

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010524811A Pending JP2010539160A (ja) 2007-09-14 2008-05-22 抗糖尿病作用を備える医薬組成物

Country Status (11)

Country Link
US (1) US8247407B2 (https=)
EP (1) EP2204173B1 (https=)
JP (1) JP2010539160A (https=)
KR (1) KR20100086981A (https=)
CN (1) CN101801373B (https=)
AU (1) AU2008297608A1 (https=)
BR (1) BRPI0815200A2 (https=)
CA (1) CA2699403A1 (https=)
MX (1) MX2010002754A (https=)
RU (1) RU2361581C2 (https=)
WO (1) WO2009035368A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2361581C2 (ru) 2007-09-14 2009-07-20 Закрытое Акционерное Общество "Мастерклон" Фармацевтическая композиция, обладающая противодиабетической, гиполипидемической, гипогликемической и гипохолестеринемической активностью, способ ее получения и способы лечения указанных заболеваний
RU2421219C1 (ru) * 2009-11-19 2011-06-20 Закрытое Акционерное Общество "Мастерклон" Ингибиторы протеинкиназы с

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3510491A (en) * 1967-02-02 1970-05-05 Sterling Drug Inc 4-(cyclicaminomethyl)-5-hydroxyindole-3-carboxylic acids and esters thereof
WO2007075102A1 (en) * 2005-12-28 2007-07-05 Zakrytoe Aktsionernoe Obschestvo 'masterklon' Medicinal agent for treating viral infections
WO2007136302A2 (en) * 2006-05-23 2007-11-29 Alla Chem, Llc Active substances, pharmaceutical composition and a method for the production and use thereof
WO2009016526A2 (ru) * 2007-06-19 2009-02-05 Alla Chem, Llc Эфиры замещенных 5-гидрокси-1н-индол-3-карбоновых кислот, фармацевтическая композиция, способ их получения и применения

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4226829A (en) * 1978-10-04 1980-10-07 Andrew Mike Renewable vaporizer for air treatment and the like
US4889286A (en) * 1988-09-19 1989-12-26 Donald Spector Controllable air freshener unit
FR2674522B1 (fr) * 1991-03-26 1993-07-16 Lipha Nouveaux derives de l'indole, procedes de preparation et medicaments les contenant.
DE19753956A1 (de) * 1997-12-05 1999-06-17 Draeger Sicherheitstech Gmbh Duftpatrone
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
CN100457730C (zh) * 2002-08-29 2009-02-04 默克公司 具有抗糖尿病活性的吲哚化合物
AR041481A1 (es) 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
CA2502269C (en) 2002-10-18 2009-12-22 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2005102320A1 (fr) 2004-04-21 2005-11-03 Zakrytoe Aktsionernoe Obschestvo 'masterklon' Medicament pour traiter des infections virales
US20060233538A1 (en) * 2005-04-14 2006-10-19 Tollens Fernando R Energized systems and devices for delivering volatile materials
US20070176015A1 (en) * 2006-01-30 2007-08-02 The Procter & Gamble Company System for delivering volatile materials
US8329689B2 (en) 2006-05-23 2012-12-11 Alexandre Vasilievich Ivachtchenko Substituted indoles and a method for the production and use thereof
WO2008100977A2 (en) * 2007-02-14 2008-08-21 N.V. Organon Carbamates therapeutic release agents as amidase inhibitors
RU2361581C2 (ru) 2007-09-14 2009-07-20 Закрытое Акционерное Общество "Мастерклон" Фармацевтическая композиция, обладающая противодиабетической, гиполипидемической, гипогликемической и гипохолестеринемической активностью, способ ее получения и способы лечения указанных заболеваний

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3510491A (en) * 1967-02-02 1970-05-05 Sterling Drug Inc 4-(cyclicaminomethyl)-5-hydroxyindole-3-carboxylic acids and esters thereof
WO2007075102A1 (en) * 2005-12-28 2007-07-05 Zakrytoe Aktsionernoe Obschestvo 'masterklon' Medicinal agent for treating viral infections
WO2007136302A2 (en) * 2006-05-23 2007-11-29 Alla Chem, Llc Active substances, pharmaceutical composition and a method for the production and use thereof
WO2009016526A2 (ru) * 2007-06-19 2009-02-05 Alla Chem, Llc Эфиры замещенных 5-гидрокси-1н-индол-3-карбоновых кислот, фармацевтическая композиция, способ их получения и применения

Also Published As

Publication number Publication date
EP2204173A1 (en) 2010-07-07
CN101801373A (zh) 2010-08-11
AU2008297608A1 (en) 2009-03-19
BRPI0815200A2 (pt) 2015-03-31
RU2361581C2 (ru) 2009-07-20
EP2204173A4 (en) 2010-12-29
US8247407B2 (en) 2012-08-21
CA2699403A1 (en) 2009-03-19
MX2010002754A (es) 2010-03-30
CN101801373B (zh) 2013-03-27
US20100168092A1 (en) 2010-07-01
EP2204173B1 (en) 2013-07-03
WO2009035368A1 (en) 2009-03-19
KR20100086981A (ko) 2010-08-02
RU2007134267A (ru) 2009-03-20

Similar Documents

Publication Publication Date Title
EP1377278B1 (en) Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv
US20230201185A1 (en) Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
KR101860120B1 (ko) 글루코키나아제 활성화제와 병용되는 메트포르민의 용도, 및 메트포르민과 글루코키나아제 활성화제를 포함하는 조성물
CZ93699A3 (cs) Způsob snižování inzulinové resistance lidí
WO2019028150A1 (en) COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
KR101567660B1 (ko) 진성 당뇨병을 치료하기 위한 병용제
EP2716302B1 (en) Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome
EP4591875A1 (en) Dual glp-1 and gip receptor agonist pharmaceutical composition and use thereof
US6399658B1 (en) Composition containing ascorbic acid
WO2023228023A1 (en) Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof
JP2010539160A (ja) 抗糖尿病作用を備える医薬組成物
CN104557944B (zh) 一种降糖药物及其制备方法
RU2646475C2 (ru) Лечение диабета I и II типа
KR100697097B1 (ko) 당뇨병 예방 또는 치료용 약학 조성물
CA3268560A1 (en) Dual glp-1 and gip receptor agonist pharmaceutical composition and use thereof
KR20250129797A (ko) 글루코오스 수치를 조절하기 위한 조성물 및 방법
JP2017128545A (ja) 併用医薬
TW201909902A (zh) 預防及／或治療代謝疾病的醫藥組合物及其用途
JPWO1998027982A1 (ja) アスコルビン酸含有組成物
JP2016034929A (ja) インスリン分泌促進剤、血糖値低減剤及び糖尿病の予防または治療剤
JP2007302614A (ja) 亜鉛−ポルフィリン誘導体錯体による経口２型糖尿病治療薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110523

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130321

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130621

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130711

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130719

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130820

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130827

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131205